Digest Network Come funziona
Network
/
Società
Sa
Non verificato

Sangamo Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaFinanzaMedicina - VarieSalute

23 comunicati stampa

Guarda tutti i comunicati
24/06/2025
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Industria
Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease
Fonte
Sangamo Therapeutics, Inc.
Emittente
Business Wire
1.00
0
12/05/2025
Web e Social Network
Telefonia e Varie
Mercato azionario
Finanza
Eventi
Igiene alimentare
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Sanità
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results
Fonte
Sangamo Therapeutics, Inc.
Emittente
Business Wire
1.00
0
12/05/2025
Finanza
Salute
Biotecnologia
Scienza
Farmaceutica
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering
Fonte
Sangamo Therapeutics, Inc.
Emittente
Business Wire
1.00
0
12/05/2025
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day
Fonte
Sangamo Therapeutics, Inc.
Emittente
Business Wire
1.00
0
06/05/2025
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Sangamo Therapeutics Announces First Quarter 2025 Earnings Call
Fonte
Sangamo Therapeutics, Inc.
Emittente
Business Wire
1.00
0
06/05/2025
Industria
Salute
Igiene alimentare
Biotecnologia
Medicina - Varie
Farmaceutica
Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease
Fonte
Sangamo Therapeutics, Inc.
Emittente
Business Wire
1.00
0
28/04/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Fonte
Sangamo Therapeutics, Inc.
Emittente
Business Wire
1.00
0
03/04/2025
Mercato del lavoro
Farmaceutica
Biotecnologia
Salute
Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
Fonte
Sangamo Therapeutics, Inc.
Emittente
Business Wire
1.00
0
17/03/2025
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
Fonte
Sangamo Therapeutics, Inc.
Emittente
Business Wire
1.00
0
06/03/2025
Mercato azionario
Eventi
Finanza
Web e Social Network
Telefonia e Varie
Farmaceutica
Biotecnologia
Salute
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference
Fonte
Sangamo Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0